KohneC.H., CunninghamD., Di CostanzoF.: Clinical determinants of survival in patients with 5fluorouracilbased treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients.Ann Oncol, 13: 308–317, 2002.
2.
KnightR.D., MillerR.R., PirottaN.: Firstline irinotecan (C), fluorouracil (F), leucovorin (L) especially improves survival (OS) in metastatic colorectal cancer (MCRC) patients (PT) with favourable prognostic indicators.Proc Am Soc Clin Oncol, 19: abst 991, 2000.
3.
BerettaG.D., FerrariV.D., BarniS.: Medical treatment of colorectal cancer in elderly (>70 years): GISCAD experience and future perspectives.Tumori, 88: S109–S112, 2002.
4.
Druker BJ for the IRIS Study Group:STI571 (Gleevec/Glivec, imatinib) versus interferon (IFN) + cytarabine as initial therapy for patients with CIVIL: results of a randomised study.Proc Am Soc Clin Oncol, 21: abst 1, 2002.
5.
SlamonD.J., GodolphinW., JonesL.A.: Studies of the HER2/neu protooncogene in human breast and ovarian cancer.Science, 244: 707–712, 1999.
6.
HortobagyiG.N.: Options for treatment of metastatic breast cancer.ASCO Educational Session, 515–521, 1999.
7.
CobleighM.A., VogelC.L., TripathyD.: Efficacy and safety of Herceptin (humanized antiHER2 antibody) as a single agent in 222 women with HER2 overexpression who relapsed following chemotherapy for metastatic breast cancer.Proc Am Soc Clin Oncol, 17: abst 97, 1998.
8.
BaselgaJ., NortonL., AlbanellJ.: Recombinant humanized antiHER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing metastatic breast cancer xenografts.Cancer Res, 58: 2825–2831, 1998.
9.
GustersonB.A., GelberR.D., GoldhirschA.: Prognostic importance of cerbB2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group.J Clin Oncol, 10: 1049–1056, 1992.
10.
MussH.B., ThorA.D., BerryD.A.: cerbB2 expression and response to adjuvant therapy in women with nodepositive early breast cancer.N Engl J Med, 330: 1260–1266, 1994.
11.
AscheleC., LonardiS., Monfardini5: Thymidylate synthase expression as a predictor of clinical response to fluoropyrimidinebased chemotherapy in advanced colorectal cancer.Cancer Treat Rev, 28: 2747, 2002.
12.
EtienneM.C., ChazalM., PuigP.L.: Prognostic value of tumoral thymidylate syntase and p53 in metastatic colorectal cancer patients receiving fluorouracilbased chemotherapy: phenotypic and genotypic analyses.J Clin Oncol, 20: 2832–2843, 2002.
13.
EdlerD., GlimeliusB., HallstromM.: Thymidylate synthase expression in colorectal cancer: a prognostic and predictive marker of benefit from adjuvant fluorouracilbased chemotherapy.J Clin Oncol, 20: 1721–1728, 2002.
14.
SalzL., RubinM., HochsterH.: Cetuximab (IMCC225) plus irinotecan (CPT 11) is active in CPT II refractory colorectal cancer (CRC) that expresses Epidermal Growth Factor Receptor (EGFR).Proc Am Soc Clin Oncol, 20: abst 7, 2001.
15.
SalzL., MeropolN.J., LoehrerP.J.: Single agent IMCC225 (Erbitux TM has activity in CPT ilrefractory colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFR).Proc Am Soc Clin Oncol, 21: abst 504, 2002.
16.
RosembergA.H., LoehrerP.J., NeedleM.N.: Erbitux (IMCC225) plus weekly irinotecan (CPT II), fluorouracil (5FU) and leucovorin (LV) in colorectal cancer (CRC) that expresses the epidermal growth factor receptor (EGFr).Proc Am Soc Clin Oncol, 21: abst 536, 2002.
HerbstR.S.: ZD1839: targeting the epidermal growth factor receptor in cancer therapy.Expert Opin Investig Drugs, 11: 837–849, 2002.
19.
BerghJ., WiklundT., EriksteinB.: Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported highdose chemotherapy as adjuvant treatment for highrisk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.Lancet, 356: 1384–1391, 2000.
20.
PetricoinE.: Application of proteomic technology to human breast cancer at the bedside multiplexed signal pathway profiling.Proc Am Assoc Cancer Res, 21: abst 681, 2002.
SteinmetzN.D.: Early prediction of tumor chemotherapy response and prognosis based on Tc99m annessin V (Apomatem) imaging after one course of chemotherapy.Proc Am Assoc Cancer Res, 21: abst 4136, 2002.
23.
SchottA.F., TaylorJ., BakerL.: Individualized chemotherapy dosing based on metabolic phenotype.Proc Am Soc Clin Oncol, 20: abst 306, 2001.
